2024 Press Releases

May 31, 2024

Humanetics to Present at the Biotechnology Innovation Organization (BIO) International Convention

February 6, 2024

Humanetics to Present at Investor and Partner Conferences

2023 Press Releases

Dec 12, 2023

Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics

Nov 14, 2023

Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer

Oct 24, 2023

Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis

Sept 19, 2023

Humanetics Corporation Publishes Clinical Trial Results of BIO 300 in Patients with NSCLC

Sept 6, 2023

Humanetics Corporation Awarded Contract from Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury

August 22, 2023

BIO 300 Featured at the 2023 Military Health System Research Symposium

May 24, 2023

BIO 300 Enhances Radiotherapy Efficacy Against Lung Tumors in a NonClinical Model

February 15, 2023

Humanetics Announces Positive Results from Independent Data Monitoring Committee

February 7, 2023

BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury

2022 Press Releases

December 16, 2022

Humanetics Corporation Presents at the MedInvest Oncology Investor Conference

November 15, 2022

Humanetics Corporation Publishes Results of Phase 1 Study of BIO 300 Oral Powder

October 25, 2022

Humanetics Corporation Presents at the 2022 Annual Radiation Research Society Meeting

October 5, 2022

FDA Clears BIO 300 Studies in Second Oncology Indication

September 22, 2022

Thomas F. Jasper Joins Board at Humanetics

August 9 2022

Jake R. Nunn Joins Board at Humanetics

July 27 2022

BIO 300 Pharmacokinetics Studies Published

June 21 2022

US Department of Defense Awards $5.1 Million to Humanetics for Continued Development of Radiation Countermeasure

May 18 2022

Humanetics Expands Clinical Sites for Long-Haul COVID-19 Trial

April 26 2022

New Data Published Comparing BIO 300 with Neulasta

April 13 2022

Humanetics Corporation Appoints Mr. Douglas W. Bryce to its Board of Advisors

2021 Press Releases

Oct 26 2021

Humanetics Corporation Adds Two New Board Members

Sept 22 2021

Humanetics Corporation Completes Phase 1 Trial

August 24 2021

Humanetics Corporation's BIO 300 Receives FDA Fast Track Designation

June 2 2021

Humanetics Receives Funding to Study New Drug for Triple Negative Lung Cancer

January 26 2021

Humanetics Receives Funding from Department of Defense for COVID-19 Studies

2020 Press Releases

October 20, 2020

Humanetics Presents New Data at Radiation Research Society Meeting

September 15, 2020

Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Board of Directors

July 23, 2020

NIAID to Fund Clinical Trial of BIO 300 in COVID-19 Patients

May 28, 2020

Humanetics Invited for Oral Presentation at ASTRO

May 6, 2020

Dr. Colin Chinn, Former Joint Staff Surgeon, Joins Humanetics Medical Advisory Board

February 19, 2020

Humanetics Acquires Assets for Radioprotectant Drug

2019 Press Releases

October 1, 2019


2018 Press Releases

October 23, 2018

Humanetics to Present at the Annual Meeting of the American Society for Radiation Oncology

October 8, 2018

Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference

September 25, 2018

Humanetics Presents Data on New Drug to Prevent Radiation Injury

July 17, 2018

Humanetics Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Exposure

April 12, 2018

Humanetics Awarded Federal Contract to Develop New Radiation Countermeasure to Protect the Lungs

February 12, 2018

Humanetics Corporation Presents at BIO CEO and Investor Conference

January 30, 2018

Humanetics Corporation Presents Data on Drug to Protect Cardiac Cells Against Toxicity from Space-like Radiation

January 11, 2018

Vice Admiral Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Humanetics' Medical Advisory Board

2017 Press Releases

October 31, 2017

Humanetics Presents Data on BIO 300

October 10, 2017

Humanetics Receives Grant From NASA

September 26, 2017

Humanetics Received $3.8 Million Grant from Department of Defense

September 12, 2017

Humanetics Awarded Patent for BIO 300

August 22, 2017

Humanetics to Present at Department of Defense Scientific Meeting

January 24, 2017

Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy

2016 Press Releases

August 10, 2016

Humanetics Received New Federal Grant to Continue Development of Radiation Countermeasure

May 17, 2016

Space Institute to Fund Testing of Radiation Protectants

2015 Press Releases

June 2, 2015

Humanetics Corporation Granted FDA Clearance To Proceed With Cancer Treatment Study

2014 Press Releases

July 9, 2014

New Grant Enables Humanetics Corporation to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients

February 25, 2014

Humanetics Corporation Enters Into Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense

January 14, 2014

Humanetics Corporation Granted Approval by the National Cancer Institute to Proceed with Cancer Treatment Study

2013 Press Releases

October 15, 2013

Humanetics Corporation Awarded Patent Enabling Oral Administration of Powerful Radioprotectant

2012 Press Releases

October 2, 2012

Humanetics Awarded Contract With National Cancer Institute